RE:RE:RE:RE:Resistance to ADCs in the treatment of solid tumors Challenges to ADC biomarker development include tumor heterogeneity and the accuracy of sampling from one biopsy at one moment in time.
ONCY's pelareorep is able to overcome the issue of tumor heterogeneity and the company's CD8+ - Tils biomarker is capable of achieving accuracy of biomarker readings from patient to patient.
Consequently, AWARE-1 data was presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting and the San Antonio Breast Cancer Symposium (SABCS) 2023 which underscored pelareorep’s MOA as an immunotherapeutic agent, and showed the expansion of T cell populations in both the tumor and blood in patients treated with pelareorep.
Importantly, translational data from pancreatic cancer patients reported at ESMO showed a correlation between tumor response and the expansion of TIL clones in the blood. This expansion of tumor resident T cells demonstrates that pelareorep treatment can increase the population of presumed tumor-reactive inflammatory cells and could become an informative biomarker of clinical outcomes to be used in future clinical studies and guide patient care.
At the end of this month ONCY will be presenting at ASCO 2024 showing biomarker representative data on pelareorep driven Tils expansion in patients with breast, pancreatic and colon cancer, and by doing so will be demonstrating how ONCY's TiLs biomarker is capable of overcoming the issues of tumor heterogeneity and its benefit of accuracy when used in multiple patients in various highly heterogeneic cancers.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36047983